These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15692997)

  • 1. Methotrexate and long-term treatment of rheumatic disease: comment on the article by Kremer.
    Ranganathan P; McLeod HL
    Arthritis Rheum; 2005 Feb; 52(2):670-1; author reply 672. PubMed ID: 15692997
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.
    Hider SL; Hoggard P; Khoo S; Back D; Bruce IN
    Arthritis Rheum; 2005 Feb; 52(2):670; author reply 672. PubMed ID: 15692979
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design.
    Hillson JL; Furst DE
    Rheum Dis Clin North Am; 1997 Nov; 23(4):757-78. PubMed ID: 9361154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of methotrexate in childhood rheumatic diseases.
    Wallace CA
    Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564
    [No Abstract]   [Full Text] [Related]  

  • 5. Toward a better understanding of methotrexate.
    Kremer JM
    Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased MDR1 P-glycoprotein expression in methotrexate resistance: comment on the article by Yudoh et al.
    Rahman P; Hefferton D; Robb D
    Arthritis Rheum; 2000 Jul; 43(7):1661-2. PubMed ID: 10902777
    [No Abstract]   [Full Text] [Related]  

  • 7. Why is methotrexate the first selection in disease-modifying antirheumatic drug therapy? Comment on the article by Wolfe et al.
    Caballero-Uribe CV
    Arthritis Care Res; 1999 Apr; 12(2):152. PubMed ID: 10513503
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of MTX in the elderly and in patients with compromised renal function.
    Morgacheva O; Furst DE
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S85-94. PubMed ID: 21044439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chinese expert-based consensus for methotrexate in rheumatic diseases].
    Chinese Association of Rheumatology and Immunology Physicians
    Zhonghua Nei Ke Za Zhi; 2018 Oct; 57(10):719-722. PubMed ID: 30293331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate--the anchor drug--an introduction.
    Pincus T; Cronstein B; Braun J
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S1-2. PubMed ID: 21044424
    [No Abstract]   [Full Text] [Related]  

  • 11. [The use of methotrexate in rheumatology: results and prospects].
    Nasonov EL
    Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172
    [No Abstract]   [Full Text] [Related]  

  • 12. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists.
    Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M
    Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current status of methotrexate].
    Fiehn C
    Z Rheumatol; 2011 Feb; 70(2):99-100. PubMed ID: 21312022
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacogenomics in pediatric rheumatology.
    Becker ML
    Curr Opin Rheumatol; 2012 Sep; 24(5):541-7. PubMed ID: 22732686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later.
    Gutiérrez-Ureña S; Espinoza LR
    Clin Exp Rheumatol; 1995; 13(3):281-4. PubMed ID: 7554552
    [No Abstract]   [Full Text] [Related]  

  • 16. Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
    Ekochin LH; Manadan AM; Aggarwal R; Sequeira W; Block JA
    J Rheumatol; 2009 Sep; 36(9):2127. PubMed ID: 19738229
    [No Abstract]   [Full Text] [Related]  

  • 17. Review: basics of drug development in rheumatology.
    Mina-Osorio P
    Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of action of methotrexate.
    Chan ES; Cronstein BN
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S5-8. PubMed ID: 24219035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate for maintenance of remission in IgG4-related disease.
    Della-Torre E; Campochiaro C; Bozzolo EP; Dagna L; Scotti R; Nicoletti R; Stone JH; Sabbadini MG
    Rheumatology (Oxford); 2015 Oct; 54(10):1934-6. PubMed ID: 26139657
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.